• 1 Executive Summary
o 1.1 Market overview
o Exhibit 01: Executive Summary – Chart on Market Overview
o Exhibit 02: Executive Summary – Data Table on Market Overview
o Exhibit 03: Executive Summary – Chart on Global Market Characteristics
o Exhibit 04: Executive Summary – Chart on Market by Geography
o Exhibit 05: Executive Summary – Chart on Market Segmentation by Route of Administration
o Exhibit 06: Executive Summary – Chart on Market Segmentation by Type
o Exhibit 07: Executive Summary – Chart on Incremental Growth
o Exhibit 08: Executive Summary – Data Table on Incremental Growth
o Exhibit 09: Executive Summary – Chart on Vendor Market Positioning
• 2 Market Landscape
o 2.1 Market ecosystem
o Exhibit 10: Parent market
o Exhibit 11: Market Characteristics
• 3 Market Sizing
o 3.1 Market definition
o Exhibit 12: Offerings of vendors included in the market definition
o 3.2 Market segment analysis
o Exhibit 13: Market segments
o 3.3 Market size 2022
o 3.4 Market outlook: Forecast for 2022-2027
o Exhibit 14: Chart on Global – Market size and forecast 2022-2027 ($ million)
o Exhibit 15: Data Table on Global – Market size and forecast 2022-2027 ($ million)
o Exhibit 16: Chart on Global Market: Year-over-year growth 2022-2027 (%)
o Exhibit 17: Data Table on Global Market: Year-over-year growth 2022-2027 (%)
• 4 Historic Market Size
o 4.1 Global GERD market 2017 – 2021
o Exhibit 18: Historic Market Size – Data Table on Global GERD market 2017 – 2021 ($ million)
o 4.2 Route of Administration Segment Analysis 2017 – 2021
o Exhibit 19: Historic Market Size – Route of Administration Segment 2017 – 2021 ($ million)
o 4.3 Drug Type Segment Analysis 2017 – 2021
o Exhibit 20: Historic Market Size – Drug Type Segment 2017 – 2021 ($ million)
o 4.4 Geography Segment Analysis 2017 – 2021
o Exhibit 21: Historic Market Size – Geography Segment 2017 – 2021 ($ million)
o 4.5 Country Segment Analysis 2017 – 2021
o Exhibit 22: Historic Market Size – Country Segment 2017 – 2021 ($ million)
• 5 Five Forces Analysis
o 5.1 Five forces summary
o Exhibit 23: Five forces analysis – Comparison between 2022 and 2027
o 5.2 Bargaining power of buyers
o Exhibit 24: Chart on Bargaining power of buyers – Impact of key factors 2022 and 2027
o 5.3 Bargaining power of suppliers
o Exhibit 25: Bargaining power of suppliers – Impact of key factors in 2022 and 2027
o 5.4 Threat of new entrants
o Exhibit 26: Threat of new entrants – Impact of key factors in 2022 and 2027
o 5.5 Threat of substitutes
o Exhibit 27: Threat of substitutes – Impact of key factors in 2022 and 2027
o 5.6 Threat of rivalry
o Exhibit 28: Threat of rivalry – Impact of key factors in 2022 and 2027
o 5.7 Market condition
o Exhibit 29: Chart on Market condition – Five forces 2022 and 2027
• 6 Market Segmentation by Route of Administration
o 6.1 Market segments
o Exhibit 30: Chart on Route of Administration – Market share 2022-2027 (%)
o Exhibit 31: Data Table on Route of Administration – Market share 2022-2027 (%)
o 6.2 Comparison by Route of Administration
o Exhibit 32: Chart on Comparison by Route of Administration
o Exhibit 33: Data Table on Comparison by Route of Administration
o 6.3 Oral – Market size and forecast 2022-2027
o Exhibit 34: Chart on Oral – Market size and forecast 2022-2027 ($ million)
o Exhibit 35: Data Table on Oral – Market size and forecast 2022-2027 ($ million)
o Exhibit 36: Chart on Oral – Year-over-year growth 2022-2027 (%)
o Exhibit 37: Data Table on Oral – Year-over-year growth 2022-2027 (%)
o 6.4 Parenteral – Market size and forecast 2022-2027
o Exhibit 38: Chart on Parenteral – Market size and forecast 2022-2027 ($ million)
o Exhibit 39: Data Table on Parenteral – Market size and forecast 2022-2027 ($ million)
o Exhibit 40: Chart on Parenteral – Year-over-year growth 2022-2027 (%)
o Exhibit 41: Data Table on Parenteral – Year-over-year growth 2022-2027 (%)
o 6.5 Market opportunity by Route of Administration
o Exhibit 42: Market opportunity by Route of Administration ($ million)
• 7 Market Segmentation by Type
o 7.1 Market segments
o Exhibit 43: Chart on Type – Market share 2022-2027 (%)
o Exhibit 44: Data Table on Type – Market share 2022-2027 (%)
o 7.2 Comparison by Type
o Exhibit 45: Chart on Comparison by Type
o Exhibit 46: Data Table on Comparison by Type
o 7.3 Antacid – Market size and forecast 2022-2027
o Exhibit 47: Chart on Antacid – Market size and forecast 2022-2027 ($ million)
o Exhibit 48: Data Table on Antacid – Market size and forecast 2022-2027 ($ million)
o Exhibit 49: Chart on Antacid – Year-over-year growth 2022-2027 (%)
o Exhibit 50: Data Table on Antacid – Year-over-year growth 2022-2027 (%)
o 7.4 PPI – Market size and forecast 2022-2027
o Exhibit 51: Chart on PPI – Market size and forecast 2022-2027 ($ million)
o Exhibit 52: Data Table on PPI – Market size and forecast 2022-2027 ($ million)
o Exhibit 53: Chart on PPI – Year-over-year growth 2022-2027 (%)
o Exhibit 54: Data Table on PPI – Year-over-year growth 2022-2027 (%)
o 7.5 H2 receptor antagonist drugs – Market size and forecast 2022-2027
o Exhibit 55: Chart on H2 receptor antagonist drugs – Market size and forecast 2022-2027 ($ million)
o Exhibit 56: Data Table on H2 receptor antagonist drugs – Market size and forecast 2022-2027 ($ million)
o Exhibit 57: Chart on H2 receptor antagonist drugs – Year-over-year growth 2022-2027 (%)
o Exhibit 58: Data Table on H2 receptor antagonist drugs – Year-over-year growth 2022-2027 (%)
o 7.6 Pro-Kinetic drugs – Market size and forecast 2022-2027
o Exhibit 59: Chart on Pro-Kinetic drugs – Market size and forecast 2022-2027 ($ million)
o Exhibit 60: Data Table on Pro-Kinetic drugs – Market size and forecast 2022-2027 ($ million)
o Exhibit 61: Chart on Pro-Kinetic drugs – Year-over-year growth 2022-2027 (%)
o Exhibit 62: Data Table on Pro-Kinetic drugs – Year-over-year growth 2022-2027 (%)
o 7.7 Market opportunity by Type
o Exhibit 63: Market opportunity by Type ($ million)
• 8 Customer Landscape
o 8.1 Customer landscape overview
o Exhibit 64: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
• 9 Geographic Landscape
o 9.1 Geographic segmentation
o Exhibit 65: Chart on Market share by geography 2022-2027 (%)
o Exhibit 66: Data Table on Market share by geography 2022-2027 (%)
o 9.2 Geographic comparison
o Exhibit 67: Chart on Geographic comparison
o Exhibit 68: Data Table on Geographic comparison
o 9.3 North America – Market size and forecast 2022-2027
o Exhibit 69: Chart on North America – Market size and forecast 2022-2027 ($ million)
o Exhibit 70: Data Table on North America – Market size and forecast 2022-2027 ($ million)
o Exhibit 71: Chart on North America – Year-over-year growth 2022-2027 (%)
o Exhibit 72: Data Table on North America – Year-over-year growth 2022-2027 (%)
o 9.4 Europe – Market size and forecast 2022-2027
o Exhibit 73: Chart on Europe – Market size and forecast 2022-2027 ($ million)
o Exhibit 74: Data Table on Europe – Market size and forecast 2022-2027 ($ million)
o Exhibit 75: Chart on Europe – Year-over-year growth 2022-2027 (%)
o Exhibit 76: Data Table on Europe – Year-over-year growth 2022-2027 (%)
o 9.5 Asia – Market size and forecast 2022-2027
o Exhibit 77: Chart on Asia – Market size and forecast 2022-2027 ($ million)
o Exhibit 78: Data Table on Asia – Market size and forecast 2022-2027 ($ million)
o Exhibit 79: Chart on Asia – Year-over-year growth 2022-2027 (%)
o Exhibit 80: Data Table on Asia – Year-over-year growth 2022-2027 (%)
o 9.6 Rest of World (ROW) – Market size and forecast 2022-2027
o Exhibit 81: Chart on Rest of World (ROW) – Market size and forecast 2022-2027 ($ million)
o Exhibit 82: Data Table on Rest of World (ROW) – Market size and forecast 2022-2027 ($ million)
o Exhibit 83: Chart on Rest of World (ROW) – Year-over-year growth 2022-2027 (%)
o Exhibit 84: Data Table on Rest of World (ROW) – Year-over-year growth 2022-2027 (%)
o 9.7 US – Market size and forecast 2022-2027
o Exhibit 85: Chart on US – Market size and forecast 2022-2027 ($ million)
o Exhibit 86: Data Table on US – Market size and forecast 2022-2027 ($ million)
o Exhibit 87: Chart on US – Year-over-year growth 2022-2027 (%)
o Exhibit 88: Data Table on US – Year-over-year growth 2022-2027 (%)
o 9.8 Germany – Market size and forecast 2022-2027
o Exhibit 89: Chart on Germany – Market size and forecast 2022-2027 ($ million)
o Exhibit 90: Data Table on Germany – Market size and forecast 2022-2027 ($ million)
o Exhibit 91: Chart on Germany – Year-over-year growth 2022-2027 (%)
o Exhibit 92: Data Table on Germany – Year-over-year growth 2022-2027 (%)
o 9.9 UK – Market size and forecast 2022-2027
o Exhibit 93: Chart on UK – Market size and forecast 2022-2027 ($ million)
o Exhibit 94: Data Table on UK – Market size and forecast 2022-2027 ($ million)
o Exhibit 95: Chart on UK – Year-over-year growth 2022-2027 (%)
o Exhibit 96: Data Table on UK – Year-over-year growth 2022-2027 (%)
o 9.10 China – Market size and forecast 2022-2027
o Exhibit 97: Chart on China – Market size and forecast 2022-2027 ($ million)
o Exhibit 98: Data Table on China – Market size and forecast 2022-2027 ($ million)
o Exhibit 99: Chart on China – Year-over-year growth 2022-2027 (%)
o Exhibit 100: Data Table on China – Year-over-year growth 2022-2027 (%)
o 9.11 Canada – Market size and forecast 2022-2027
o Exhibit 101: Chart on Canada – Market size and forecast 2022-2027 ($ million)
o Exhibit 102: Data Table on Canada – Market size and forecast 2022-2027 ($ million)
o Exhibit 103: Chart on Canada – Year-over-year growth 2022-2027 (%)
o Exhibit 104: Data Table on Canada – Year-over-year growth 2022-2027 (%)
o 9.12 Market opportunity by geography
o Exhibit 105: Market opportunity by geography ($ million)
• 10 Drivers, Challenges, and Trends
o 10.1 Market drivers
o 10.2 Market challenges
o 10.3 Impact of drivers and challenges
o Exhibit 106: Impact of drivers and challenges in 2022 and 2027
o 10.4 Market trends
• 11 Vendor Landscape
o 11.1 Overview
o 11.2 Vendor landscape
o Exhibit 107: Overview on Criticality of inputs and Factors of differentiation
o 11.3 Landscape disruption
o Exhibit 108: Overview on factors of disruption
o 11.4 Industry risks
o Exhibit 109: Impact of key risks on business
• 12 Vendor Analysis
o 12.1 Vendors covered
o Exhibit 110: Vendors covered
o 12.2 Market positioning of vendors
o Exhibit 111: Matrix on vendor position and classification
o 12.3 Abbott Laboratories
o Exhibit 112: Abbott Laboratories – Overview
o Exhibit 113: Abbott Laboratories – Business segments
o Exhibit 114: Abbott Laboratories – Key news
o Exhibit 115: Abbott Laboratories – Key offerings
o Exhibit 116: Abbott Laboratories – Segment focus
o 12.4 Alkem Laboratories Ltd.
o Exhibit 117: Alkem Laboratories Ltd. – Overview
o Exhibit 118: Alkem Laboratories Ltd. – Business segments
o Exhibit 119: Alkem Laboratories Ltd. – Key news
o Exhibit 120: Alkem Laboratories Ltd. – Key offerings
o Exhibit 121: Alkem Laboratories Ltd. – Segment focus
o 12.5 Apotex Inc.
o Exhibit 122: Apotex Inc. – Overview
o Exhibit 123: Apotex Inc. – Product / Service
o Exhibit 124: Apotex Inc. – Key offerings
o 12.6 AstraZeneca Plc
o Exhibit 125: AstraZeneca Plc – Overview
o Exhibit 126: AstraZeneca Plc – Product / Service
o Exhibit 127: AstraZeneca Plc – Key news
o Exhibit 128: AstraZeneca Plc – Key offerings
o 12.7 Aurobindo Pharma Ltd.
o Exhibit 129: Aurobindo Pharma Ltd. – Overview
o Exhibit 130: Aurobindo Pharma Ltd. – Product / Service
o Exhibit 131: Aurobindo Pharma Ltd. – Key offerings
o 12.8 Bayer AG
o Exhibit 132: Bayer AG – Overview
o Exhibit 133: Bayer AG – Business segments
o Exhibit 134: Bayer AG – Key news
o Exhibit 135: Bayer AG – Key offerings
o Exhibit 136: Bayer AG – Segment focus
o 12.9 Cipla Ltd.
o Exhibit 137: Cipla Ltd. – Overview
o Exhibit 138: Cipla Ltd. – Business segments
o Exhibit 139: Cipla Ltd. – Key news
o Exhibit 140: Cipla Ltd. – Key offerings
o Exhibit 141: Cipla Ltd. – Segment focus
o 12.10 Dr Reddys Laboratories Ltd.
o Exhibit 142: Dr Reddys Laboratories Ltd. – Overview
o Exhibit 143: Dr Reddys Laboratories Ltd. – Business segments
o Exhibit 144: Dr Reddys Laboratories Ltd. – Key offerings
o Exhibit 145: Dr Reddys Laboratories Ltd. – Segment focus
o 12.11 Eisai Co. Ltd.
o Exhibit 146: Eisai Co. Ltd. – Overview
o Exhibit 147: Eisai Co. Ltd. – Business segments
o Exhibit 148: Eisai Co. Ltd. – Key offerings
o Exhibit 149: Eisai Co. Ltd. – Segment focus
o 12.12 Fresenius SE and Co. KGaA
o Exhibit 150: Fresenius SE and Co. KGaA – Overview
o Exhibit 151: Fresenius SE and Co. KGaA – Business segments
o Exhibit 152: Fresenius SE and Co. KGaA – Key news
o Exhibit 153: Fresenius SE and Co. KGaA – Key offerings
o Exhibit 154: Fresenius SE and Co. KGaA – Segment focus
o 12.13 GlaxoSmithKline Plc
o Exhibit 155: GlaxoSmithKline Plc – Overview
o Exhibit 156: GlaxoSmithKline Plc – Business segments
o Exhibit 157: GlaxoSmithKline Plc – Key offerings
o Exhibit 158: GlaxoSmithKline Plc – Segment focus
o 12.14 iNova Pharmaceuticals
o Exhibit 159: iNova Pharmaceuticals – Overview
o Exhibit 160: iNova Pharmaceuticals – Product / Service
o Exhibit 161: iNova Pharmaceuticals – Key offerings
o 12.15 Johnson and Johnson
o Exhibit 162: Johnson and Johnson – Overview
o Exhibit 163: Johnson and Johnson – Business segments
o Exhibit 164: Johnson and Johnson – Key news
o Exhibit 165: Johnson and Johnson – Key offerings
o Exhibit 166: Johnson and Johnson – Segment focus
o 12.16 Lupin Ltd.
o Exhibit 167: Lupin Ltd. – Overview
o Exhibit 168: Lupin Ltd. – Product / Service
o Exhibit 169: Lupin Ltd. – Key news
o Exhibit 170: Lupin Ltd. – Key offerings
o 12.17 Perrigo Co. Plc
o Exhibit 171: Perrigo Co. Plc – Overview
o Exhibit 172: Perrigo Co. Plc – Business segments
o Exhibit 173: Perrigo Co. Plc – Key news
o Exhibit 174: Perrigo Co. Plc – Key offerings
o Exhibit 175: Perrigo Co. Plc – Segment focus
• 13 Appendix
o 13.1 Scope of the report
o 13.2 Inclusions and exclusions checklist
o Exhibit 176: Inclusions checklist
o Exhibit 177: Exclusions checklist
o 13.3 Currency conversion rates for US$
o Exhibit 178: Currency conversion rates for US$
o 13.4 Research methodology
o Exhibit 179: Research methodology
o Exhibit 180: Validation techniques employed for market sizing
o Exhibit 181: Information sources
o 13.5 List of abbreviations
o Exhibit 182: List of abbreviations
Exhibits:
Exhibits1: Executive Summary – Chart on Market Overview
Exhibits2: Executive Summary – Data Table on Market Overview
Exhibits3: Executive Summary – Chart on Global Market Characteristics
Exhibits4: Executive Summary – Chart on Market by Geography
Exhibits5: Executive Summary – Chart on Market Segmentation by Route of Administration
Exhibits6: Executive Summary – Chart on Market Segmentation by Type
Exhibits7: Executive Summary – Chart on Incremental Growth
Exhibits8: Executive Summary – Data Table on Incremental Growth
Exhibits9: Executive Summary – Chart on Vendor Market Positioning
Exhibits10: Parent market
Exhibits11: Market Characteristics
Exhibits12: Offerings of vendors included in the market definition
Exhibits13: Market segments
Exhibits14: Chart on Global – Market size and forecast 2022-2027 ($ million)
Exhibits15: Data Table on Global – Market size and forecast 2022-2027 ($ million)
Exhibits16: Chart on Global Market: Year-over-year growth 2022-2027 (%)
Exhibits17: Data Table on Global Market: Year-over-year growth 2022-2027 (%)
Exhibits18: Historic Market Size – Data Table on Global GERD market 2017 – 2021 ($ million)
Exhibits19: Historic Market Size – Route of Administration Segment 2017 – 2021 ($ million)
Exhibits20: Historic Market Size – Drug Type Segment 2017 – 2021 ($ million)
Exhibits21: Historic Market Size – Geography Segment 2017 – 2021 ($ million)
Exhibits22: Historic Market Size – Country Segment 2017 – 2021 ($ million)
Exhibits23: Five forces analysis – Comparison between 2022 and 2027
Exhibits24: Chart on Bargaining power of buyers – Impact of key factors 2022 and 2027
Exhibits25: Bargaining power of suppliers – Impact of key factors in 2022 and 2027
Exhibits26: Threat of new entrants – Impact of key factors in 2022 and 2027
Exhibits27: Threat of substitutes – Impact of key factors in 2022 and 2027
Exhibits28: Threat of rivalry – Impact of key factors in 2022 and 2027
Exhibits29: Chart on Market condition – Five forces 2022 and 2027
Exhibits30: Chart on Route of Administration – Market share 2022-2027 (%)
Exhibits31: Data Table on Route of Administration – Market share 2022-2027 (%)
Exhibits32: Chart on Comparison by Route of Administration
Exhibits33: Data Table on Comparison by Route of Administration
Exhibits34: Chart on Oral – Market size and forecast 2022-2027 ($ million)
Exhibits35: Data Table on Oral – Market size and forecast 2022-2027 ($ million)
Exhibits36: Chart on Oral – Year-over-year growth 2022-2027 (%)
Exhibits37: Data Table on Oral – Year-over-year growth 2022-2027 (%)
Exhibits38: Chart on Parenteral – Market size and forecast 2022-2027 ($ million)
Exhibits39: Data Table on Parenteral – Market size and forecast 2022-2027 ($ million)
Exhibits40: Chart on Parenteral – Year-over-year growth 2022-2027 (%)
Exhibits41: Data Table on Parenteral – Year-over-year growth 2022-2027 (%)
Exhibits42: Market opportunity by Route of Administration ($ million)
Exhibits43: Chart on Type – Market share 2022-2027 (%)
Exhibits44: Data Table on Type – Market share 2022-2027 (%)
Exhibits45: Chart on Comparison by Type
Exhibits46: Data Table on Comparison by Type
Exhibits47: Chart on Antacid – Market size and forecast 2022-2027 ($ million)
Exhibits48: Data Table on Antacid – Market size and forecast 2022-2027 ($ million)
Exhibits49: Chart on Antacid – Year-over-year growth 2022-2027 (%)
Exhibits50: Data Table on Antacid – Year-over-year growth 2022-2027 (%)
Exhibits51: Chart on PPI – Market size and forecast 2022-2027 ($ million)
Exhibits52: Data Table on PPI – Market size and forecast 2022-2027 ($ million)
Exhibits53: Chart on PPI – Year-over-year growth 2022-2027 (%)
Exhibits54: Data Table on PPI – Year-over-year growth 2022-2027 (%)
Exhibits55: Chart on H2 receptor antagonist drugs – Market size and forecast 2022-2027 ($ million)
Exhibits56: Data Table on H2 receptor antagonist drugs – Market size and forecast 2022-2027 ($ million)
Exhibits57: Chart on H2 receptor antagonist drugs – Year-over-year growth 2022-2027 (%)
Exhibits58: Data Table on H2 receptor antagonist drugs – Year-over-year growth 2022-2027 (%)
Exhibits59: Chart on Pro-Kinetic drugs – Market size and forecast 2022-2027 ($ million)
Exhibits60: Data Table on Pro-Kinetic drugs – Market size and forecast 2022-2027 ($ million)
Exhibits61: Chart on Pro-Kinetic drugs – Year-over-year growth 2022-2027 (%)
Exhibits62: Data Table on Pro-Kinetic drugs – Year-over-year growth 2022-2027 (%)
Exhibits63: Market opportunity by Type ($ million)
Exhibits64: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
Exhibits65: Chart on Market share by geography 2022-2027 (%)
Exhibits66: Data Table on Market share by geography 2022-2027 (%)
Exhibits67: Chart on Geographic comparison
Exhibits68: Data Table on Geographic comparison
Exhibits69: Chart on North America – Market size and forecast 2022-2027 ($ million)
Exhibits70: Data Table on North America – Market size and forecast 2022-2027 ($ million)
Exhibits71: Chart on North America – Year-over-year growth 2022-2027 (%)
Exhibits72: Data Table on North America – Year-over-year growth 2022-2027 (%)
Exhibits73: Chart on Europe – Market size and forecast 2022-2027 ($ million)
Exhibits74: Data Table on Europe – Market size and forecast 2022-2027 ($ million)
Exhibits75: Chart on Europe – Year-over-year growth 2022-2027 (%)
Exhibits76: Data Table on Europe – Year-over-year growth 2022-2027 (%)
Exhibits77: Chart on Asia – Market size and forecast 2022-2027 ($ million)
Exhibits78: Data Table on Asia – Market size and forecast 2022-2027 ($ million)
Exhibits79: Chart on Asia – Year-over-year growth 2022-2027 (%)
Exhibits80: Data Table on Asia – Year-over-year growth 2022-2027 (%)
Exhibits81: Chart on Rest of World (ROW) – Market size and forecast 2022-2027 ($ million)
Exhibits82: Data Table on Rest of World (ROW) – Market size and forecast 2022-2027 ($ million)
Exhibits83: Chart on Rest of World (ROW) – Year-over-year growth 2022-2027 (%)
Exhibits84: Data Table on Rest of World (ROW) – Year-over-year growth 2022-2027 (%)
Exhibits85: Chart on US – Market size and forecast 2022-2027 ($ million)
Exhibits86: Data Table on US – Market size and forecast 2022-2027 ($ million)
Exhibits87: Chart on US – Year-over-year growth 2022-2027 (%)
Exhibits88: Data Table on US – Year-over-year growth 2022-2027 (%)
Exhibits89: Chart on Germany – Market size and forecast 2022-2027 ($ million)
Exhibits90: Data Table on Germany – Market size and forecast 2022-2027 ($ million)
Exhibits91: Chart on Germany – Year-over-year growth 2022-2027 (%)
Exhibits92: Data Table on Germany – Year-over-year growth 2022-2027 (%)
Exhibits93: Chart on UK – Market size and forecast 2022-2027 ($ million)
Exhibits94: Data Table on UK – Market size and forecast 2022-2027 ($ million)
Exhibits95: Chart on UK – Year-over-year growth 2022-2027 (%)
Exhibits96: Data Table on UK – Year-over-year growth 2022-2027 (%)
Exhibits97: Chart on China – Market size and forecast 2022-2027 ($ million)
Exhibits98: Data Table on China – Market size and forecast 2022-2027 ($ million)
Exhibits99: Chart on China – Year-over-year growth 2022-2027 (%)
Exhibits100: Data Table on China – Year-over-year growth 2022-2027 (%)
Exhibits101: Chart on Canada – Market size and forecast 2022-2027 ($ million)
Exhibits102: Data Table on Canada – Market size and forecast 2022-2027 ($ million)
Exhibits103: Chart on Canada – Year-over-year growth 2022-2027 (%)
Exhibits104: Data Table on Canada – Year-over-year growth 2022-2027 (%)
Exhibits105: Market opportunity by geography ($ million)
Exhibits106: Impact of drivers and challenges in 2022 and 2027
Exhibits107: Overview on Criticality of inputs and Factors of differentiation
Exhibits108: Overview on factors of disruption
Exhibits109: Impact of key risks on business
Exhibits110: Vendors covered
Exhibits111: Matrix on vendor position and classification
Exhibits112: Abbott Laboratories – Overview
Exhibits113: Abbott Laboratories – Business segments
Exhibits114: Abbott Laboratories – Key news
Exhibits115: Abbott Laboratories – Key offerings
Exhibits116: Abbott Laboratories – Segment focus
Exhibits117: Alkem Laboratories Ltd. – Overview
Exhibits118: Alkem Laboratories Ltd. – Business segments
Exhibits119: Alkem Laboratories Ltd. – Key news
Exhibits120: Alkem Laboratories Ltd. – Key offerings
Exhibits121: Alkem Laboratories Ltd. – Segment focus
Exhibits122: Apotex Inc. – Overview
Exhibits123: Apotex Inc. – Product / Service
Exhibits124: Apotex Inc. – Key offerings
Exhibits125: AstraZeneca Plc – Overview
Exhibits126: AstraZeneca Plc – Product / Service
Exhibits127: AstraZeneca Plc – Key news
Exhibits128: AstraZeneca Plc – Key offerings
Exhibits129: Aurobindo Pharma Ltd. – Overview
Exhibits130: Aurobindo Pharma Ltd. – Product / Service
Exhibits131: Aurobindo Pharma Ltd. – Key offerings
Exhibits132: Bayer AG – Overview
Exhibits133: Bayer AG – Business segments
Exhibits134: Bayer AG – Key news
Exhibits135: Bayer AG – Key offerings
Exhibits136: Bayer AG – Segment focus
Exhibits137: Cipla Ltd. – Overview
Exhibits138: Cipla Ltd. – Business segments
Exhibits139: Cipla Ltd. – Key news
Exhibits140: Cipla Ltd. – Key offerings
Exhibits141: Cipla Ltd. – Segment focus
Exhibits142: Dr Reddys Laboratories Ltd. – Overview
Exhibits143: Dr Reddys Laboratories Ltd. – Business segments
Exhibits144: Dr Reddys Laboratories Ltd. – Key offerings
Exhibits145: Dr Reddys Laboratories Ltd. – Segment focus
Exhibits146: Eisai Co. Ltd. – Overview
Exhibits147: Eisai Co. Ltd. – Business segments
Exhibits148: Eisai Co. Ltd. – Key offerings
Exhibits149: Eisai Co. Ltd. – Segment focus
Exhibits150: Fresenius SE and Co. KGaA – Overview
Exhibits151: Fresenius SE and Co. KGaA – Business segments
Exhibits152: Fresenius SE and Co. KGaA – Key news
Exhibits153: Fresenius SE and Co. KGaA – Key offerings
Exhibits154: Fresenius SE and Co. KGaA – Segment focus
Exhibits155: GlaxoSmithKline Plc – Overview
Exhibits156: GlaxoSmithKline Plc – Business segments
Exhibits157: GlaxoSmithKline Plc – Key offerings
Exhibits158: GlaxoSmithKline Plc – Segment focus
Exhibits159: iNova Pharmaceuticals – Overview
Exhibits160: iNova Pharmaceuticals – Product / Service
Exhibits161: iNova Pharmaceuticals – Key offerings
Exhibits162: Johnson and Johnson – Overview
Exhibits163: Johnson and Johnson – Business segments
Exhibits164: Johnson and Johnson – Key news
Exhibits165: Johnson and Johnson – Key offerings
Exhibits166: Johnson and Johnson – Segment focus
Exhibits167: Lupin Ltd. – Overview
Exhibits168: Lupin Ltd. – Product / Service
Exhibits169: Lupin Ltd. – Key news
Exhibits170: Lupin Ltd. – Key offerings
Exhibits171: Perrigo Co. Plc – Overview
Exhibits172: Perrigo Co. Plc – Business segments
Exhibits173: Perrigo Co. Plc – Key news
Exhibits174: Perrigo Co. Plc – Key offerings
Exhibits175: Perrigo Co. Plc – Segment focus
Exhibits176: Inclusions checklist
Exhibits177: Exclusions checklist
Exhibits178: Currency conversion rates for US$
Exhibits179: Research methodology
Exhibits180: Validation techniques employed for market sizing
Exhibits181: Information sources
Exhibits182: List of abbreviations
